Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Pathogenic bacterium in gut or vagina” is not a specific molecular target but denotes any bacterial species capable of causing infection or disease within these body sites. The human gut and vaginal microbiomes contain hundreds of bacterial species; while most are commensal or beneficial, a subset can become pathogenic, especially when the microbial community is disrupted (a state called dysbiosis). In the gut, common pathogenic genera include *Klebsiella*, *Bacteroides* (e.g., *B. fragilis*), *Clostridioides* (e.g., *C. difficile*), *Escherichia* (e.g., *E. coli*), and others[1][4][2][5]. In the vagina, *Gardnerella vaginalis*, *Atopobium vaginae*, and certain anaerobes are associated with infections like bacterial vaginosis. These bacteria are classified taxonomically by phylum, genus, and species, but “pathogenic bacteria” is a functional rather than a molecular or structural category[1][4][2][6]. Pathogenic bacteria in these locations act via various mechanisms: producing toxins, evading or modulating immune responses, outcompeting commensals, and inducing inflammation. They contribute to diseases such as gastroenteritis, inflammatory bowel disease, bacterial vaginosis, and may play a role in systemic conditions (e.g., liver disease, cardiovascular disease) via immune activation and translocation of bacterial products such as LPS[6]. Since “pathogenic bacteria in gut/vagina” is a descriptive group rather than a single defined target molecule or receptor, it does not have a canonical full name, molecular abbreviation, or a unified mechanism or drug specificity. Each individual pathogen (such as *Clostridioides difficile* or *Gardnerella vaginalis*) would have specific molecular characteristics, biomarkers, and drug sensitivities. For research or clinical purposes, exact pathogen identification is needed to select targeted therapies and monitor efficacy[1][4][6].
Disruption of cell wall synthesis, Inhibition of protein synthesis, Restoration of healthy microbiota balance, Immune modulation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterium in gut or vagina.